Medical therapy of pituitary adenomas: effects on tumor shrinkage.
The efficacy of dopamine-agonists (DA) in patients with prolactinomas and that of somatostatin analogues (SSA) in those with GH- and TSH-secreting adenomas is well established. More recently, data are accumulating suggesting a potential therapeutic role of DA also in patients with ACTH-secreting and clinically non-functioning (NFA) pituitary adenomas. This review aims at summarizing published results of DA and SSA on tumor shrinkage in patients with different histotypes of pituitary adenomas. Results of tumor shrinkage are of clinical relevance as tumor size is the one of the most important determinant of surgical outcome. While reduction of tumor size more than 50% of baseline size in macroprolactinomas treated with DA is a frequent finding in patients with GH-secreting adenomas treated with SSA tumor shrinkage only recently is becoming frequent thanks to the availability of depot formulations. Data on tumor shrinkage in patients with TSH-secreting adenomas treated with SSA are limited because of the rarity of these tumors. Very recently, DA have been reported of some efficacy also in patients with ACTH-secreting adenomas but data are still very limited. NFA respond very scantly to both DA and SSA even if receptors targeting these drugs are present. Whether this is due to limited receptor number or alterations of post-receptor pathway is still unknown.
Colao
Annamaria
A
Department of Molecular & Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy. colao@unina.it
Pivonello
Rosario
R
Di Somma
Carolina
C
Savastano
Silvia
S
Grasso
Ludovica F S
LF
Lombardi
Gaetano
G
D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D018491:Dopamine Agonists / Q000627:therapeutic use; D013006:Growth Hormone / Q000378:metabolism; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013972:Thyrotropin / Q000378:metabolism
D018491:Dopamine Agonists; D006728:Hormones; D013004:Somatostatin; D000324:Adrenocorticotropic Hormone; D013972:Thyrotropin; D013006:Growth Hormone
J Clin Endocrinol Metab. 1994 Nov;79(5):1416-23
7962337
J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8
12107192
J Endocrinol Invest. 2009 Mar;32(3):202-9
19542735
J Clin Endocrinol Metab. 2007 May;92(5):1592-9
17311860
Clin Cancer Res. 2007 May 1;13(9):2738-44
17473207
Nature. 1989 Dec 21-28;342(6252):923-6
2531847
J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62
18413427
Expert Opin Investig Drugs. 2002 Jun;11(6):787-800
12036422
Clin Endocrinol (Oxf). 2006 Feb;64(2):209-14
16430722
Endocr Pract. 2007 Jul-Aug;13(4):396-402
17669717
J Clin Endocrinol Metab. 1991 Oct;73(4):850-6
1653785
J Clin Endocrinol Metab. 1994 Feb;78(2):398-403
8106629
J Endocrinol Invest. 2006 Oct;29(9):826-30
17114915
N Engl J Med. 2005 Jun 9;352(23):2457-8
15944436
Clin Endocrinol (Oxf). 1986 Nov;25(5):561-72
3621623
J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7
18211974
Endocrinology. 1994 Jan;134(1):401-10
7903933
J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63
15613435
Clin Endocrinol (Oxf). 1992 Feb;36(2):171-6
1348979
Endocr Rev. 2006 Aug;27(5):485-534
16705142
J Clin Endocrinol Metab. 1983 Jan;56(1):1-10
6292253
Expert Opin Pharmacother. 2000 Mar;1(3):555-74
11249538
Eur J Endocrinol. 2007 Nov;157(5):579-87
17984237
J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61
11701688
J Endocrinol Invest. 1999 Jan;22(1):64-5
10090139
Clin Endocrinol (Oxf). 2002 Oct;57(4):425-41
12354124
J Endocrinol Invest. 2001 Mar;24(3):183-7
11314748
J Clin Endocrinol Metab. 1997 Nov;82(11):3574-9
9360509
J Clin Endocrinol Metab. 1992 Nov;75(5):1310-7
1430093
J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403
16449332
J Endocrinol Invest. 1999 Apr;22(4):306-9
10342366
J Clin Endocrinol Metab. 1988 Mar;66(3):636-9
2895119
J Clin Endocrinol Metab. 2006 Jun;91(6):2112-8
16537687
J Clin Endocrinol Metab. 1998 Feb;83(2):374-8
9467544
J Endocrinol Invest. 1997 Oct;20(9):537-46
9413808
Clin Endocrinol (Oxf). 1988 Nov;29(5):467-76
2908102
J Clin Endocrinol Metab. 2004 Feb;89(2):638-45
14764775
J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91
10770186
J Clin Endocrinol Metab. 2004 May;89(5):2452-62
15126577
Eur J Endocrinol. 2008 May;158(5):595-603
18426817
Horm Res. 1992;38(1-2):78-83
1306522
Eur J Endocrinol. 2005 Apr;152(4):645-54
15817922
Drugs. 2003;63(22):2473-99
14609359
Ann Intern Med. 1990 May 1;112(9):668-73
1970714
J Clin Endocrinol Metab. 1985 Oct;61(4):666-71
2863281
Eur J Endocrinol. 2002 May;146(5):707-16
11980628
Endocrine. 2003 Apr;20(3):279-83
12721508
J Clin Endocrinol Metab. 1994 Jul;79(1):113-8
8027215
J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53
11397898
J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52
10852458
J Clin Endocrinol Metab. 2001 Nov;86(11):5194-200
11701676
J Endocrinol Invest. 1999 Dec;22(11):860-5
10710275
N Engl J Med. 2003 Nov 20;349(21):2023-33
14627787
Horm Res. 2000;53 Suppl 3:76-87
10971110
Endocr Rev. 1996 Dec;17(6):610-38
8969971
Eur J Endocrinol. 1996 Nov;135(5):548-52
8980156
J Physiol Paris. 2000 May-Aug;94(3-4):205-10
11087998
J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10
15827109
Endocr Rev. 1993 Aug;14(4):443-58
7693447
J Clin Endocrinol Metab. 1998 Jan;83(1):248-52
9435450
J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8
12213843
J Endocrinol Invest. 2006 Dec;29(11):1017-20
17259801
J Endocrinol Invest. 1999 Jan;22(1):40-7
10090136
J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68
18477663
Eur J Endocrinol. 2005 Aug;153(2):187-93
16061822
J Clin Endocrinol Metab. 1997 Feb;82(2):518-23
9024247
Ann Oncol. 2001;12 Suppl 2:S31-6
11762349
N Engl J Med. 1996 Jan 25;334(4):246-54
8532003
Drugs. 1994 Mar;47(3):425-45
7514973
Endocrinol Metab Clin North Am. 2008 Mar;37(1):135-49, ix
18226734
J Endocrinol Invest. 2005;28(11 Suppl International):5-9
16625838
Clin Endocrinol (Oxf). 1997 Nov;47(5):589-98
9425399
J Clin Endocrinol Metab. 1987 Jul;65(1):65-73
3034958
Ann Intern Med. 1993 Aug 1;119(3):236-40
8323093
Eur J Endocrinol. 1998 Nov;139(5):516-21
9849816
Eur J Endocrinol. 2007 Jul;157(1):39-46
17609400
J Clin Endocrinol Metab. 2004 Sep;89(9):4493-502
15356054
J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83
15070930
J Clin Endocrinol Metab. 1996 Aug;81(8):3084-90
8768879
Metabolism. 1996 Aug;45(8 Suppl 1):67-71
8769387
Clin Endocrinol (Oxf). 1994 Mar;40(3):421-8
8187308
Pituitary. 2004;7(2):107-10
15761660
Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9
17524029
Physiol Rev. 1998 Jan;78(1):189-225
9457173
Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 3):2S5-12
12037501
J Clin Endocrinol Metab. 1991 Dec;73(6):1248-55
1720125
Acta Endocrinol (Copenh). 1991 Apr;124(4):487-91
2031445
Neurosurgery. 1997 Oct;41(4):786-95; discussion 796-7
9316039
Endocr Rev. 1992 May;13(2):220-40
1352243
J Endocrinol Invest. 1993 Jul-Aug;16(7):541-3
8227984
J Clin Endocrinol Metab. 1992 Nov;75(5):1318-25
1358910
Mayo Clin Proc. 1997 Oct;72(10):893-900
9379690
J Clin Endocrinol Metab. 2007 Jan;92(1):65-9
17032724
J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22
10404830
Eur J Endocrinol. 2007 Apr;156 Suppl 1:S57-S63
17413190
Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45
10762286
Clin Endocrinol (Oxf). 2001 Jan;54(1):23-30
11167922
J Endocrinol Invest. 1999 Mar;22(3):176-83
10219884
Neurosurgery. 1989 Dec;25(6):948-50
2532309